Renal Insufficiency, ChronicPhase 1NCT01551446
Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes
A Phase 1 study testing Bardoxolone Methyl in people with Renal Insufficiency, Chronic and Diabetes Mellitus, Type 2, run by Biogen.
Trial summary
This study is to evaluate the variability of several pharmacodynamic measures of kidney function, cardiovascular function, cerebral perfusion, and haemodynamics. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
- What is being tested?
- Bardoxolone Methyl
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- 30 Apr 2012to 30 Nov 2012
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Screening eGFR ≥15.0 and ≤60.0 mL/min/1.73 m2;
- A history of type 2 diabetes; diagnosis should have been made at ≥ 30 years of age (if diabetes developed at a younger age, a fasting C-peptide level must be ≥ 0.1 ng/mL to confirm type 2 diabetes);
- Male or female patients at least 18 years of age;
- Treatment with an angiotensin converting enzyme (ACE) inhibitor and/or an angiotensin II receptor blocker (ARB) for at least 6 weeks prior to Study Day 1. The dosage of ACE inhibitor and/or ARB must be stable for 2 weeks prior to and/or during screening (i.e., no change in dosage or medication). Patients not taking an ACE inhibitor and/or ARB, or taking an ACE inhibitor and/or ARB at levels below the goal dose set by K/DOQI guidelines must have a documented medical contraindication (e.g., hyperkalemia, hypotension), which the investigator must provide and discuss with a medical monitor prior to Study Day 1. Patients not taking an ACE inhibitor and/or ARB because of a medical contraindication must have discontinued treatment at least 8 weeks prior to Study Day 1;
- Mean systolic blood pressure (SBP) ≤160 mmHg and ≥105 mmHg and mean diastolic blood pressure (DBP) ≤90 mmHg during screening; both mean SBP and mean DBP (determined as the average of three readings) must be within the described range during the screening period;
- Willing to practice methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) during screening, while taking study drug and for at least 30 days after the last dose of study drug is ingested;
Show all 9Show fewer
- Serum magnesium level must be ≥1.3 mEq/L (0.65 mmol/L) during the screening period;
- Willing and able to cooperate with all aspects of the protocol;
- Willing to and able to give written informed consent for study participation.
Who cannot join
- Type 1 diabetes mellitus (juvenile onset). If a history of diabetic ketoacidosis exists, a fasting C-peptide level must confirm type 2 diabetes;
- Known non-diabetic renal disease (e.g., known polycystic kidney disease, family history of a hereditary form of kidney disease, or congenital absence of one kidney) [nephrosclerosis superimposed on diabetic kidney disease is acceptable];
- Ongoing clinical investigation with evidence (e.g., unexplained hematuria or red blood cell or white blood cell casts) suggesting non-diabetic renal disease other than nephrosclerosis;
- History of a renal donation, transplant or a planned transplant from a living donor during the study;
- Albumin/creatinine (ACR) during screening period greater than 3500 mg/g (395.5 mg/mmol);
- Hemoglobin A1c level >11.0% (97 mmol/mol) during screening period;
Show all 29Show fewer
- Acute dialysis or acute kidney injury within 12 weeks prior to screening or during screening;
- Clinical signs and/or symptoms of uremia and expected need for renal replacement therapy within 6 weeks following Study Day 1, as assessed by the investigator;
- Recently active cardiovascular disease defined as:
- Unstable angina pectoris within 12 weeks before Study Day 1;
- Myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty/stent within 12 weeks before Study Day 1;
- Cerebrovascular accident, including transient ischemic attack within 12 weeks before Study Day 1;
- Clinical diagnosis of severe obstructive valvular heart disease or severe obstructive hypertrophic cardiomyopathy;
- Atrioventricular block, 2o or 3o;
- Administration of a contrast agent that may induce nephropathy within 30 days prior to Study Day 1 or planned during the study;
- Systemic immunosuppression for more than 2 weeks, cumulatively, within the 12 weeks prior to Study Day 1 or anticipated need for immunosuppression during the study;
- Total bilirubin, aspartate transaminase (AST), or alanine transaminase (ALT) level greater than the upper limit of normal (ULN) or alkaline phosphatase level >2x ULN on ANY screening laboratory test result;
- Female patients who are pregnant, intend to become pregnant during the study, or are nursing;
- BMI < 18.5 kg/m2;
- Known hypersensitivity to any component of the study drug;
- Current history of drug or alcohol abuse, as assessed by the investigator;
- Clinically significant infection requiring intravenous administration of antibiotics or hospitalization within 6 weeks prior to or during the screening period;
- Hepatitis B surface antigen positive;
- Diagnosis or treatment of a malignancy in the past 5 years, excluding non-melanoma skin cancer and carcinoma in situ of the cervix, or a condition highly likely to transform into a malignancy during the course of the study;
- A clinical condition that, in the judgment of the investigator, could potentially pose a health risk to the patient while involved in the study;
- Participation in a clinical study involving any intervention within 30 days prior to Study Day 1, concurrent participation in such a study, or participation in a prior clinical study involving bardoxolone methyl in any form;
- Unable to understand verbal or written information in English;
- Mental incapacity to consent;
- Contraindications to MRI (implants, pace makers, claustrophobia).
About this study
This study is to evaluate the variability of several pharmacodynamic measures of kidney function, cardiovascular function, cerebral perfusion, and haemodynamics.
- Being tested
- Bardoxolone Methyl
- Medical subject headings
- Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bardoxolone MethylDrug
Oral, once daily
| Study group | Role | What they receive |
|---|---|---|
| Bardoxolone Methyl 20mg | Experimental | Not described Receives: Drug: Bardoxolone Methyl |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in renal perfusion
The change in renal perfusion measured by ASL-MRI Scanning
Measured: 20 weeks
Secondary outcomes (9)
Change in cardiac function
The change in cardiac function measured by cardiac MRI scanning
Measured: 20 weeks
Change in cerebral perfusion
The change in cerebral perfusion measured by cerebral ASL MRI
Measured: 20 weeks
Change in haemodynamic variables
The change in the following haemodynamic variables: non-invasive measurement of cardiac output, heart rate, blood pressure and baroreflex sensitivity
Measured: 20 weeks
Change in arterial stiffness
The change in arterial stiffness measured using cartoi-femoral Pulsewave Velocity Assessment and Augmentation Index
Measured: 20 weeks
Change in body composition
The change in body composition measured using Bioelectrical Impedance Analysis
Measured: 20 weeks
Number of participants with adverse events and serious adverse events
Measured: 20 weeks
Plasma concentration of bardoxolone methyl
Measured: 20 weeks
Change in cerebral white matter microstructure
Measured: 20 weeks
Change in total body water
The change in total body water measured using Bioelectrical Impedance Analysis
Measured: 20 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2012 (estimated)
- Study start30 Apr 2012
- Primary completion30 Nov 2012
- Study completion30 Nov 2012
Why it stopped: IDMC recommendation for safety concerns
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Renal Insufficiency, ChronicStudies of the same condition, open and under way.
- More trials run by BiogenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Biogen
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01551446
- Sponsor's protocol ID
- 402-C-1103
- Status last verified
- May 2025
- First submitted
- 5 Mar 2012
- Last updated
- 29 May 2025
- Results posted
- No
- Individual data sharing
- Yes: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Study at a glance
From the registry record, last updated by the sponsor on 29 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes
- ClinicalTrials.gov ID
- NCT01551446
- Acronym / sponsor ID
- 402-C-1103
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: IDMC recommendation for safety concerns
- Enrolment
- 0 participants (actual)
- Lead sponsor
- BiogenIndustry (pharma, biotech, devices)
- Study start
- 30 Apr 2012 (actual)
- Primary completion
- 30 Nov 2012 (actual)
- Study completion
- 30 Nov 2012 (actual)
- First posted
- 12 Mar 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is to evaluate the variability of several pharmacodynamic measures of kidney function, cardiovascular function, cerebral perfusion, and haemodynamics.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Bardoxolone Methyl 20mg | Experimental | Drug: Bardoxolone Methyl |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Screening eGFR ≥15.0 and ≤60.0 mL/min/1.73 m2;
- A history of type 2 diabetes; diagnosis should have been made at ≥ 30 years of age (if diabetes developed at a younger age, a fasting C-peptide level must be ≥ 0.1 ng/mL to confirm type 2 diabetes);
- Male or female patients at least 18 years of age;
- Treatment with an angiotensin converting enzyme (ACE) inhibitor and/or an angiotensin II receptor blocker (ARB) for at least 6 weeks prior to Study Day 1. The dosage of ACE inhibitor and/or ARB must be stable for 2 weeks prior to and/or during screening (i.e., no change in dosage or medication). Patients not taking an ACE inhibitor and/or ARB, or taking an ACE inhibitor and/or ARB at levels below the goal dose set by K/DOQI guidelines must have a documented medical contraindication (e.g., hyperkalemia, hypotension), which the investigator must provide and discuss with a medical monitor prior to Study Day 1. Patients not taking an ACE inhibitor and/or ARB because of a medical contraindication must have discontinued treatment at least 8 weeks prior to Study Day 1;
- Mean systolic blood pressure (SBP) ≤160 mmHg and ≥105 mmHg and mean diastolic blood pressure (DBP) ≤90 mmHg during screening; both mean SBP and mean DBP (determined as the average of three readings) must be within the described range during the screening period;
Key exclusion criteria (29 listed)
- Type 1 diabetes mellitus (juvenile onset). If a history of diabetic ketoacidosis exists, a fasting C-peptide level must confirm type 2 diabetes;
- Known non-diabetic renal disease (e.g., known polycystic kidney disease, family history of a hereditary form of kidney disease, or congenital absence of one kidney) [nephrosclerosis superimposed on diabetic kidney disease is acceptable];
- Ongoing clinical investigation with evidence (e.g., unexplained hematuria or red blood cell or white blood cell casts) suggesting non-diabetic renal disease other than nephrosclerosis;
- History of a renal donation, transplant or a planned transplant from a living donor during the study;
- Albumin/creatinine (ACR) during screening period greater than 3500 mg/g (395.5 mg/mmol);
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bardoxolone MethylOral, once daily | Drug | Bardoxolone Methyl 20mg |
Primary outcome
Change in renal perfusion
Time frame: 20 weeks
The change in renal perfusion measured by ASL-MRI Scanning
9 secondary outcomes
Change in cardiac function
Time frame: 20 weeks
Change in cerebral perfusion
Time frame: 20 weeks
Change in haemodynamic variables
Time frame: 20 weeks
Change in arterial stiffness
Time frame: 20 weeks
Change in body composition
Time frame: 20 weeks
Number of participants with adverse events and serious adverse events
Time frame: 20 weeks
Plasma concentration of bardoxolone methyl
Time frame: 20 weeks
Change in cerebral white matter microstructure
Time frame: 20 weeks
Change in total body water
Time frame: 20 weeks
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 May 2025.
- Individual participant dataSharing planned: Yes. In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Related trials for Renal Insufficiency, Chronic
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
RecruitingPhase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Not yet recruiting
An Individuation Intervention to Reduce Socioeconomic Disparities in Chronic Kidney Disease Care
Chronic Kidney Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Bardoxolone Methyl in people with Renal Insufficiency, Chronic and Diabetes Mellitus, Type 2, run by Biogen.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 29 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 29 May 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in renal perfusion (time frame: 20 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2025.